Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493435 | 0.87 | CHRM1 (0.35) | BCL2A1ESR2AOC3SLC6A4SLC6A2 | |
| SCHEMBL492732 | 0.86 | ESR2 (0.36) | BCL2A1ESR2GAAHPGDSLC6A4 | |
| SCHEMBL493536 | 0.81 | BCL2A1 (0.45) | BCL2A1AOC3SMN1; SMN2GAAHPGD | |
| SCHEMBL1326713 | 0.80 | BCL2A1 (0.46) | BCL2A1AOC3SMN1; SMN2GAAHPGD | |
| SCHEMBL3582113 | 0.79 | BCL2A1 (0.45) | BCL2A1SMN1; SMN2GAAHPGDSLC6A4 | |
| SCHEMBL2307385 | 0.78 | BCL2A1 (0.43) | BCL2A1AOC3SMN1; SMN2GAAHPGD | |
| SCHEMBL493030 | 0.78 | BCL2A1 (0.41) | BCL2A1AOC3SMN1; SMN2GAAHPGD | |
| SCHEMBL492739 | 0.78 | BCL2A1 (0.43) | BCL2A1AOC3SMN1; SMN2GAAHPGD | |
| SCHEMBL492740 | 0.78 | BCL2A1 (0.43) | BCL2A1AOC3SMN1; SMN2GAAHPGD | |
| SCHEMBL1327427 | 0.76 | BCL2A1 (0.43) | BCL2A1AOC3SMN1; SMN2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384544-B | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH | 2014-01-22 | — | — | CN | claimed |
| US-8058475-B2 | Substituted cyclohexylmethyl compounds | GRUENENTHAL GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1989174-B1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-08-03 | — | — | EP | claimed |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | GRUENENTHAL GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| JP-2009520720-A | — | — | 2009-05-28 | — | — | JP | claimed |
| CN-101384544-A | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | CN | claimed |
| EP-1989174-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| WO-2007079930-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| CN-101384544-B | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH | 2014-01-22 | — | — | CN | disclosed |
| US-8058475-B2 | Substituted cyclohexylmethyl compounds | GRUENENTHAL GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1989174-B1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | GRUENENTHAL GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
| CN-101384544-A | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | CN | disclosed |
| EP-1989174-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007079930-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | BCL2A1 1972/4885ESR2 1010/4885AOC3 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.